Novartis’s Canakinumab Fails In COVID-19 Pneumonia Patients
Dexamethasone Remains Only Proven Therapy In Severe Disease
Executive Summary
Drug fails to save lives in study and follows disappointments from Roche and Regeneron/Sanofi's IL-6 inhibitors.
You may also be interested in...
Novartis Hit By Canakinumab NSCLC Miss
The Swiss firm's canakinumab has proved to be an effective treatment for several inflammation-driven rare conditions but disappointment from the CANOPY-2 trial suggests that cancer will follow cardiovascular as an indication where the therapy falls by the wayside.
Novartis’s JAK Inhibitor Fails In COVID, Raising Questions On Lilly Prospects
The Phase III failure of ruxolotinib contrasts with encouraging results and emergency use authorization for Lilly’s JAK inhibitor baricitinib in combination therapy.
Coronavirus Update: Moderna Ready For Interim Analysis, Brazil Resumes SinoVac Trial
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.